Neumora Therapeutics, Inc. Financials
NMRA
All currency values in $ millions unless otherwise noted
| Income Statement | DEC 2025 | DEC 2024 ~2.5:1 split | DEC 2023 ~2.4:1 split | DEC 2022 |
|---|---|---|---|---|
| General & Administrative | $60 | $63 | $45 | $31 |
| Research & Development | $176 | $201 | $143 | $92 |
| Total Operating Expenses | $241 | $263 | $252 | $136 |
| Operating Income | -$241 | -$263 | -$252 | -$136 |
| Non-Operating | ||||
| Net Interest Expense | $6 | $20 | – | – |
| Other Non-Operating Income (Expense) | -$2 | -$0 | $16 | $5 |
| EBT (Earnings Before Tax) | -$237 | -$244 | -$236 | -$131 |
| Income Tax Expense | $0 | $0 | $0 | – |
| Net Income | ||||
| Net Income | -$237 | -$244 | -$236 | -$131 |
| EPS (Basic) | -$1.45 | -$1.53 | -$3.63 | -$4.81 |
| EPS (Diluted) | -$1.45 | -$1.53 | -$3.63 | -$4.81 |
| Weighted Avg Shares (Basic) | 163.4M | 159.4M | 65.0M | 27.2M |
| Weighted Avg Shares (Diluted) | 163.4M | 159.4M | 65.0M | 27.2M |
| Shares Outstanding | 163.4M | 159.4M | 65.0M | 27.2M |
Neumora Therapeutics (NMRA) financials: revenue, profit and margins
Neumora Therapeutics (NMRA) generated about n/a in revenue and -$190 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Neumora Therapeutics profitable?+
Neumora Therapeutics reported about -$190 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 11 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 16 Nov 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with NMRA
Held by ETFs
NMRA is in 5 US ETFs. The largest of them, with NMRA's weight in each:
Spot a number that looks wrong? Check it in NMRA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NMRA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.